ArticleAnnals of internal medicine2016

ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.

Paul ShekellePubMed ↗Publisher ↗

No numbers read from the abstract.